[68Ga]Pentixafor–PET–based SUVs and TBR of biopsy-proven residual gastric MALT lymphomas after H pylori eradication; comparative control group [68Ga]Pentixafor–PET metrics
| . | Mean ± SE* . | Range* . | Correlation with IHC CXCR4+ cell %† . | P† . |
|---|---|---|---|---|
| MALT lymphoma | ||||
| SUVmax | 9.1 ± 0.74 | 3.3-18.2 | 0.51 | .008 |
| SUVmean | 4.5 ± 0.26 | 2.5-7.8 | 0.52 | .006 |
| TBRblood-max | 3.6 ± 0.28 | 1.3-7.3 | 0.42 | .014 |
| TBRliver-max | 4.2 ± 0.33 | 1.6-8.0 | 0.38 | .029 |
| TBRblood-mean | 5.1 ± 0.42 | 1.8-11.2 | 0.55 | .010 |
| TBRliver-mean | 7.4 ± 0.85 | 2.4-13.8 | 0.41 | .044 |
| Controls | ||||
| Gastric SUVmax | 3.2 ± 0.13 | 2.1-4.1 | NA | NA |
| Gastric SUVmean | 1.0 ± 0.10 | 1.2-2.7 | NA | NA |
| SBRblood-max | 1.1 ± 0.06 | 0.6-1.6 | NA | NA |
| SBRliver-max | 1.3 ± 0.06 | 0.8-1.7 | NA | NA |
| SBRblood-mean | 1.8 ± 0.11 | 0.9-2.9 | NA | NA |
| SBRliver-mean | 2.3 ± 0.14 | 1.3-3.3 | NA | NA |
| . | Mean ± SE* . | Range* . | Correlation with IHC CXCR4+ cell %† . | P† . |
|---|---|---|---|---|
| MALT lymphoma | ||||
| SUVmax | 9.1 ± 0.74 | 3.3-18.2 | 0.51 | .008 |
| SUVmean | 4.5 ± 0.26 | 2.5-7.8 | 0.52 | .006 |
| TBRblood-max | 3.6 ± 0.28 | 1.3-7.3 | 0.42 | .014 |
| TBRliver-max | 4.2 ± 0.33 | 1.6-8.0 | 0.38 | .029 |
| TBRblood-mean | 5.1 ± 0.42 | 1.8-11.2 | 0.55 | .010 |
| TBRliver-mean | 7.4 ± 0.85 | 2.4-13.8 | 0.41 | .044 |
| Controls | ||||
| Gastric SUVmax | 3.2 ± 0.13 | 2.1-4.1 | NA | NA |
| Gastric SUVmean | 1.0 ± 0.10 | 1.2-2.7 | NA | NA |
| SBRblood-max | 1.1 ± 0.06 | 0.6-1.6 | NA | NA |
| SBRliver-max | 1.3 ± 0.06 | 0.8-1.7 | NA | NA |
| SBRblood-mean | 1.8 ± 0.11 | 0.9-2.9 | NA | NA |
| SBRliver-mean | 2.3 ± 0.14 | 1.3-3.3 | NA | NA |